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109Vascular endothelial growth factor-C derived from
CD11bþ cells induces therapeutic improvements
in a murine model of hind limb ischemia
Go Kuwahara, MD,a,b Hitomi Nishinakamura, PhD,b Daibo Kojima, MD, PhD,b
Tadashi Tashiro, MD, PhD,a and Shohta Kodama, MD, PhD,b Fukuoka, Japan
Objective: The use of bone marrow cells (BMCs) in therapeutic angiogenesis has been studied extensively. However, the
critical paracrine effects of this treatment are still unclear. Therefore, we studied autotransfusable cells that produce
vascular endothelial growth factor (VEGF), especially VEGF-C.
Methods:Male C57BL/6 mice with hind limb ischemia were administered intramuscular injections of phosphate-buffered
saline as controls, or unsorted BMCs, sorted CD11bD, or CD11bL cells from BMCs, and recombinant VEGF-C. To
evaluate the treatments, perfusion was measured by laser Doppler scanning performed on days 0, 1, 3, 7, 14, 21, and 28.
A functional assay was performed in parallel, with mice traversing an enclosed walkway. Capillary density was determined
by directly counting vessels stained positive with von Willebrand factor at individual time points. Lymphangiogenesis was
assessed by LYVE-1 positive cells.
Results: Postischemic recovery of hind limb perfusion signiﬁcantly improved in BMC, CD11bD, and VEGF-C treatment
groups comparedwith thecontrol groups, as assessedby laserDoppler scanning.Onearlyoperativedays1 and3, thebloodﬂow
recovery ratiowashigher in theCD11bD-treatedgroupcomparedwithBMCandVEGF-Ctreatment groups. In the functional
assay, the VEGF-C group dramatically recovered compared with the control group. The capillary/myoﬁber ratio in the thigh
muscle and number of LYVE-1 positive cells was higher in the CD11bD and VEGF-C groups than in controls. Furthermore,
expression of VEGF-A, VEGF-C, and VEGF receptor messenger ribonucleic acid and protein was observed in CD11bD cells.
Conclusions: The VEGF-C derived from CD11bD cells play a critical role in angiogenesis and lymphangiogenesis in
amurinemodel of hind limb ischemia. Consequently, treatment with self-CD11bD cells accelerated recovery from ischemia
and may be a promising therapeutic strategy for peripheral arterial disease patients. (J Vasc Surg 2013;57:1090-9.)
Clinical Relevance: The incidence of peripheral arterial disease is rapidly increasing commensurate with a rapid rise in the
elderly population. Conventional therapy has a 5-year prognosis and survival rates <30%; thus, an alternative approach,
termed therapeutic angiogenesis, has been developed, consisting of local injection of bone marrow cells (BMCs).
However, the precise therapeutic mechanism, including paracrine effects, is unclear. We focused on CD11bD cells, which
promote regulation of vascular endothelial growth factor-A and especially vascular endothelial growth factor-C. CD11bD
treatment could reduce the total number of cell injections and improve the early operative points of blood ﬂow compared
with conventional therapy with BMCs. Consequently, CD11bD treatment accelerates recovery from ischemia and is
helpful in reducing the need for repeated aspiration of BMCs.The incidence of peripheral arterial disease (PAD) is
rapidly increasing commensurate with a rapid rise in the
elderly population.1 Critical limb ischemia is the end stage
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0blood ﬂow results in ischemic rest pain, ulcers, and signiﬁ-
cant risk of limb loss. In patients with severe limb-
threatening ischemia, whether surgical or endovascular
revascularization treatment is applied to improve the blood
ﬂow must be determined. Approximately 20% to 30%
of patients with critical limb ischemia are not considered
candidates for vascular or endovascular procedures, which
often leaves amputation as the ﬁnal option.2 Leg amputation
due to atherosclerotic PAD results in an acute mortality
rate of around 30% and a 5-year prognosis with
survival rates<30%.3 Therefore, in addition to conventional
therapy, which includes percutaneous intervention and
surgical bypass, novel therapies are needed to treat this
disorder.
Alternative approaches, termed therapeutic angiogen-
esis, have been developed, which include local intramuscular
injection of autologous adult bone marrow cells (BMCs)
and growth factors such as vascular endothelial growth
factor (VEGF)-A.4,5 Accumulating evidence has indicated
that BMCs contribute to neovascularization and tissue
repair through paracrine/autocrine mechanisms rather
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However, the optimal cell type is unknown. The role of
VEGF-A in angiogenesis has been studied extensively
in vivo and in vitro.9 Despite supporting evidence from
animal studies, there has been a discrepancy in translating
the angiogenic capacity of growth factors into beneﬁts for
individuals with PAD.10 The reason for these disappointing
results is the side effects of VEGF-A, which increases perme-
ability, causing signiﬁcant edema in PAD patients.5,11
Otherwise, VEGF-C is considered an important lymphan-
giogenic factor that enhances venous return and lymphatic
drainage from the ischemic limbs, which may have the
potential to improve ischemic limbs in PAD patients.
In this report, we focused on bone marrow-derived
CD11bþ cells, which produce VEGF-C and VEGF-D,12
and the critical lymphangiogenic factor VEGF-C, which
could improve venous congestion and lymphedema. We
hypothesized that VEGF-C derived from CD11bþ cells
may be important in angio- and lymphangiogenesis of
ischemic tissue. Using a murine model of hind limb
ischemia, we assessed whether CD11bþ cells promoted
angio- and lymphangiogenesis. Furthermore, we demon-
strated that lymphangiogenesis induced by VEGF-C
through the VEGFR-3 signaling pathway has a synergistic
therapeutic effect in a murine model of hind limb ischemia.
METHODS
Animal model and procedures. Twelve-week-old
male C57BL/6N mice were purchased from Charles River
Laboratories (Saga, Japan). The care of mice and experi-
mental procedures complied with the “Principles of Labo-
ratory Animal Care” (Guide for the Care and Use of
Laboratory Animals, National Institutes of Health publica-
tion 86-23, 1985). The experimental protocol was
approved by the Animal Care and Use Committee of
Fukuoka University. Mouse hind limb ischemia was
induced as previously described.13,14 Brieﬂy, the left
femoral artery and vein were gently excised from the
proximal portion of the femoral artery to the distal portion
of the saphenous artery. The remaining arterial branches,
including the perforator arteries, also were excised. The
contralateral hind limb served as an internal control.
Measurement of hind limb blood ﬂow. Blood ﬂow
was monitored using a laser Doppler perfusion imager
(Moor Instruments Ltd, Devon, United Kingdom). Blood
ﬂowwas expressed as a ratio of the ischemic and nonischemic
hind limbs. In additional experiments, mice were random-
ized to receive systemic administration of neutralizing anti-
body to VEGFR-2 (800 mg of DC101; BioXCell, West
Lebanon,NH) twice aweek for 2weeks (n¼ 5 per group).15
Enrichment of CD11bD cells from BMCs and ﬂow
cytometric analysis. After 8-week-old male C57BL/6N
mice were sacriﬁced, bone marrow from the femur and
tibia was collected. CD11bþ cells that include macro-
phages and dendritic cells in the BMCs were stained with
ﬂuorescein isothiocyanate-conjugated rat anti-mouse
CD11b (BD Biosciences, San Jose, Calif) and anti-
ﬂuorescein isothiocyanate MicroBeads (Miltenyi Biotec,Gladbach, Germany) and enriched by using a magnetic cell
sorter (MACS; Miltenyi Biotec). Then the cells were
analyzed by ﬂow cytometry (BD FACSCanto II; BD
Biosciences) using Cell Quest software. Data were analyzed
using FlowJo software (BD Biosciences).16
In vivo tissue implant angiogenesis assay. The mice
were randomly divided into ﬁve groups (n ¼ 5 per group).
Treatment groups received phosphate-buffered saline
(PBS; controls), 1  107 unselected BMCs, 1  106
CD11bþ cells, 1  106 CD11b cells, or 5 mg of
recombinant human VEGF-C (Cys156Ser; R&D Systems,
Minneapolis, Minn) in a total volume of 100 mL in PBS,
injected percutaneously into the thigh muscle at three
points using a 27-gauge needle.
Clinical score of hind limb ischemia in mice. Mice
were examined at 7 and 14 days after induction of hind
limb ischemia. Functional grading was performed accord-
ing to the Tarlov scale.17 To precisely evaluate the
mobility of mice after limb ischemia, we used a previously
described scoring system, where 0 ¼ normal, 1 ¼ pale foot
or gait abnormalities, 2 ¼ gangrenous tissue in less than
half of the foot without lower limb necrosis, 3 ¼ gangre-
nous tissue in less than half of the foot with lower limb
necrosis, 4 ¼ gangrenous tissue in more than half of the
foot, and 5 ¼ loss of half of the lower limb.18 The clinical
outcome of all mice was observed and recorded at the same
points as blood ﬂow measurement.
Gait analysis. Mice were assessed for functional
recovery 7 days after hind limb ischemia by determining
the extent to which the injured limb was used for walking.
Each mouse traversed an enclosed walkway (CatWalk
system; Noldus, Wageningen, The Netherlands) three
times. In this system, a light-emitting diode from a ﬂuo-
rescent lamp illuminates the inside of a glass ﬂoor plate of
the walkway. Light is reﬂected downward at the site of the
paw in contact with the upper surface of the glass plate, the
intensity of which is proportional to the relative force being
exerted by the paw. Light reﬂection was recorded with
a video camera and analyzed to determine the duration of
paw contact with the ﬂoor and the mean pixel intensity at
contact.19
Immunoﬂuorescent staining. Mice were sacriﬁced at
7 and 14 days after surgery. The thigh adductor muscles of
the legs were harvested, ﬁxed in 10% formaldehyde solu-
tion, and embedded in parafﬁn. Muscle ﬁber number was
examined in sections stained with hematoxylineeosin,
and the mean counts from ﬁve separate ﬁelds in four
distinct areas in each specimen were calculated. Capillary
endothelial cells were identiﬁed by immunohistochemical
staining with von Willebrand factor antibody (DAKO,
Glostrup, Denmark).20 Capillary density was expressed as
the ratio of von Willebrand factor positive cells to myo-
ﬁbers per high power ﬁeld (magniﬁcation 400).
Furthermore, lymphangiogenesis was assessed by LYVE-1
antibody (Relia Tech GmbH, Wolfenbüttel, Germany).21
Immunohistochemistry. The thigh adductor muscles
of native and treated mice were ﬁxed in 10% formaldehyde
solution, processed, and embedded in parafﬁn. The sections
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anti-VEGFR-2, and anti-VEGFR-3 antibody (Abcam,
Tokyo, Japan), then detected by diaminobenzidine staining.
Reverse transcription-polymerase chain reaction
analysis. Total RNA was isolated from thigh muscle with
PureLink RNA Mini kit (Life Technologies, Carlsbad,
Calif). Reverse transcription-polymerase chain reaction
(RT-PCR) was carried out using high-capacity cDNA
reverse transcription kits (Applied Biosystems, Carlsbad,
Calif). The following oligonucleotides were used: glycer-
aldehyde-3-phosphate dehydrogenase (G3PDH): 50-ACA
TCAAGAAGGTAGTGAAGCTGGC-30, 50-TTCAAGA-
GATTAGGGCTCCCTAGG-30; VEGFR-1: 50-TACCTC
AAGAGCAAACGTGAC-30, 50-CGATGAATGCACTTT
CTGG-30; VEGFR-2: 50-CTAAGGGCATGGAGTTCT
TG-30, 50-CATACAGGAAACAGGTGAGGT-30; and VE
GFR-3: 50-CTATGGCTGAGCCCAATGAC-30, 50-ACCT
TATCAAAGATGCTCTCGG-30.22 The annealing temper-
ature and the PCR cycles were G3PDH: 60C, 28 cycles;
VEGFR-1: 60.8C, 35 cycles; VEGFR-2: 58.1C, 30 cycles;
and VEGFR-3: 60.8C, 35 cycles.
Immunoblotting. Thigh muscle and embryo were
homogenized at 4C in lysis buffer (Cell Signaling Tech-
nology, Danvers, Mass) with protease inhibitor cocktail
(Roche, Mannheim, Germany) and then centrifuged at
13,000 rpm for 15 minutes. The supernatant was collected.
Protein concentrations were measured using a bicinchoni-
nate acid protein assay kit (ThermoFisher Scientiﬁc,
Waltham, Mass). Equal amounts of protein from each
experimental group were loaded for sodium dodecyl
sulfate polyacrylamide gel electrophoresis, followed by
immunoblotting. The membranes were proved with
anti-VEGFR-1 (R&D Systems), anti-VEGFR-2 (Cell
Signaling Technology ), anti-VEGFR-3 (eBioscience, San
Diego, Calif) and anti-b-actin (Cell Signaling Technology).
Membrane signals were detected using the ECL reagent
(GE Healthcare, Buckinghamshire, United Kingdom).
Enzyme-linked immunosorbent assay. Thigh muscle
was homogenized at 4C in PBS with protease inhibitor
cocktail (Roche) and then centrifuged at 13,000 rpm for
15 minutes. The supernatant was collected. Protein levels
for VEGF-A and VEGF-C were determined by enzyme-
linked immunosorbent assay (R&D Systems and Life
Science Inc, St. Petersburg, Fla, respectively) as previously
described.23
Statistical analysis. Statistical analysis was performed
using PASW Statistics 18.0 (IBM Japan, Tokyo, Japan).
A two-tailed Student t-test, paired Student t-test, or one-
way analysis of variance and Mann-Whitney U test were
used for statistical analysis. P < .05 was considered statis-
tically signiﬁcant.
RESULTS
Effect of implanted BMCs in ischemic limb
muscle. Before the experiments, all mice had similar base-
line blood ﬂow in the leg and functional status. In the
PBS control group, the blood ﬂow decreased rapidly after
limb ischemia and returned slowly, achieving 60% ofpreprocedural ﬂow after 4 weeks (Fig 1, A). Blood ﬂow
recovery was signiﬁcantly improved in mice treated with
1  107 BMCs at 7 and 14 days after the operative
procedure. At 21 and 28 days, the BMC-treated group
demonstrated a trend toward increased blood ﬂow
recovery compared with the control group, but this was
not signiﬁcantly different (Fig 1, A).
Recovery of blood ﬂow in the ischemic limbs
treated with CD11bD cells. To determine whether
BMCs contained enriched CD11bþ cells, we performed
ﬂow cytometric analysis of CD11bþ cells from total
BMCs. Unseparated BMCs contained 29.59% CD11bþ
cells. After MACS sorting, the purity of CD11bþ cells
was 95.56% (Fig 1, B). We next measured the recovery
blood ﬂow in ischemic limbs treated with puriﬁed CD11bþ
cells. Mice were treated with 1 106 CD11bþ cells,
CD11b cells, or PBS for controls. To determine the cell
number of CD11bþ cells, three different numbers of
CD11bþ cells (1  104, 1  105, and 1  106) were
investigated as a preliminary study. The 1  106 CD11bþ
cells had a statistically signiﬁcant difference as the lowest
number in a preliminary study. The control animals were
measured at each time point. On the earliest operative days
1 and 3, the blood ﬂow recovery ratio was higher in the
CD11bþ-treated group compared with the control and
CD11b groups. Moreover, blood ﬂow recovery was
signiﬁcantly improved in the CD11bþ-treated group
compared with the control and CD11b groups at 7 and
14 days after the operative procedure. At 21 and 28 days,
there was no signiﬁcant difference between blood ﬂow
recovery of the CD11bþ-treated group compared with the
control and CD11b groups (Fig 1, C). Thus, mice treated
with 1  106 CD11bþ cells showed an improved blood
ﬂow, the same as the 1  107 BMC-treated mice at
multiple time points (Fig 1, A and C).
Protein expression of VEGF-A, VEGF-C, VEGFR-
1, VEGFR-2, and VEGFR-3. To identify the production
of VEGF-A and VEGF-C from CD11bþ cells, we measured
levels of VEGF-A and VEGF-C in cultured supernatant
from CD11bþ and CD11b cells. Enzyme-linked immu-
nosorbent assay analyses showed signiﬁcantly increased
levels of VEGF-A and VEGF-C in the cultured supernatant
of CD11bþ cells compared with CD11b cells. Although
VEGF-A was secreted by both CD11bþ and CD11b cells,
VEGF-C was not secreted from cultured CD11b cells
(Fig 2, A). The VEGFR-1 and VEGFR-3 messenger ribo-
nucleic acid (mRNA) were expressed in CD11bþ cells, but
VEGFR-2 mRNA was not detected in either CD11bþ or
CD11b cells (Fig 2, B). Furthermore, we conﬁrmed that
CD11bþ and CD11b cells expressed VEGFR-1 and
VEGFR-3 protein (Fig 2, C). These results suggest the
possibility that CD11bþ cells are activated by autocrine
VEGF-A and VEGF-C via VEGFR-1 and VEGFR-3,
respectively.
Recovery of blood ﬂow in ischemic limbs treated
with recombinant VEGF-C. We compared treatment of
mice with 5 mg of recombinant VEGF-C with PBS-
treated controls in restoring blood ﬂow to ischemic hind
Fig 1. Recovery of blood ﬂow in ischemic limbs treated with bone marrow cells (BMCs) and CD11bþ cells derived
from BMCs. A and C, Representative laser Doppler perfusion images taken at indicated intervals for the phosphate-
buffered saline (PBS) control group, unselected BMCs group, CD11b group, and CD11bþ group. Blood perfu-
sion in the ischemic hind limbs was markedly increased in the unselected BMCs and CD11bþ groups compared with
the control and CD11b groups, respectively. Quantitative analysis of hind limb blood perfusion demonstrated an
increase in the ischemic/nonischemic ratio, which was signiﬁcantly higher in the BMCs group compared with the
control group at postoperative days 7 and 14 (day 7: 38.9% 6 9.0% vs 14.8 6 6.7%; P < .01; day 14: 72.2% 6 7.4% vs
31.1 6 12.0%; P < .05; n ¼ 5-7). The increase in the ischemic/nonischemic ratio was signiﬁcantly higher in the
CD11bþ group compared with the CD11b group at postoperative days 1, 3, 7, and 14 ( day 1: 17.1% 6 4.0% vs
12.361.7%; P < .05; day 3: 26.4%6 3.1% vs 12.3%6 7.2%; P < .05; day 7: 48.4%6 16.0% vs 20.7%6 8.6%; P < .01;
day 14: 85.7% 6 23.3% vs 45.7% 6 4.8%; P < .01; n ¼ 5-7). Data are given as mean 6 SEM, n ¼ 5-7 per group. *P <
.05; **P < .01; ***P < .001. B, Flow cytometric analysis of CD11bþ macrophages from BMCs. The purity of
subpopulations of the enriched CD11bþ macrophages was approximately 95% according to the FACS analysis.
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doses of VEGF-C, adjusted to 3, 5, 12.5, and 25 mg, were
injected as a preliminary study. The 5 mg of VEGF-C had
a statistically signiﬁcant difference as the lowest dose in
a preliminary study. The control animals were measured at
each time point. Blood perfusion in the ischemic hind
limbs was markedly increased in the 5 mg VEGF-C-treated
group compared with controls at multiple time points. The
increase in the ischemia/nonischemic ratio was signiﬁcantly
upregulated in the 5 mg VEGF-C-treated group compared
with the control group at 7 and 14 days after operative
procedure. At 21 and 28 days, the 5 mg VEGF-C-treated
group showed a better recovery ratio than the controlgroup, but there was no signiﬁcant difference in the
recovery of blood ﬂow between the groups (Fig 3, A).
Functional recovery following hind limb ischemia
by intramuscular injection of VEGF-C. To evaluate
more precisely the functional deﬁcits and ischemic grade
of ischemic limbs, we tested mice according to the Tarlov
score for function and Ischemic score for ischemia. Using
the Tarlov score, the VEGF-C-treated group showed
a signiﬁcantly increased functional status at 7 and 14 days
compared with the control group. Using the Ischemic
scoring system, the VEGF-C group showed a signiﬁcantly
increased level of ischemic tissue grade at day 7 compared
with the control group. At 14 days, there were no
Fig 2. Expression of vascular endothelial growth factor (VEGF)-
A, VEGF-C, VEGFR-1, VEGFR-2, and VEGFR-3 in CD11b
and CD11bþ cells. A, Concentration of VEGF-A and VEGF-C
secreted by CD11b or CD11bþ cells. After magnetic cell sort-
ing (MACS), 1  105 CD11b or CD11bþ cells were incubated
for 7 days and the supernatant analyzed by enzyme-linked
immunosorbent assay (n ¼ 3; mean [standard deviation];
***P < . 001). B, Representative messenger ribonucleic acid
(mRNA) of VEGFR-1, VEGFR-2, and VEGFR-3 from CD11b
and CD11bþ cells. Glyceraldehyde-3-phosphate dehydrogenase
(G3PDH) was used as an internal control. Reverse transcription-
polymerase chain reaction is representative of three separate
experiments. C, Representative immunoblotting images for
VEGFR-1, VEGFR-2, and VEGFR-3 from CD11b and CD11bþ
cells. After MACS sorting, 5  106 CD11b and CD11bþ cells
were lysed and examined by immunoblotting analysis. The staining
of b-actin was used as an internal control. Blots are representative
of three separate experiments. E11 and E13 used for positive
control means embryonic day 11 and 13.
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between the VEGF-C and control groups. In addition,
there were no signiﬁcant differences in functional status
and in ischemic tissue grade at 7 and 14 days between the
VEGF-C and CD11bþ-treated groups (Fig 3, B).
Furthermore, we performed gait analysis in the VEGF-
C-treated and control groups. The control (PBS) group
could not use the injured limb (left hind limb) for walking,
whereas mice from the VEGF-C-treated group could use
both hind limbs for walking. The blue arrowhead in the
contact duration map in Fig 3, C, depicts the pixel intensity
generated by the mouse paws upon contact with the glass
ﬂoor. Pixel intensity generated by the three uninjured limbs
in the control group was higher compared with the VEGF-
C-treated group. These ﬁndings indicate that functional
recovery of ischemic limbs in the VEGF-C-treated group
was dramatically improved compared with the control
group. In quantitative analysis, paw contact time wassigniﬁcantly prolonged in ischemic limbs of the VEGF-
C-treated group compared with the control group (0.17 6
0.13 s vs 0.02 6 0.05 s; P < .05). In addition, paw
intensity was signiﬁcantly higher in the ischemic limbs of
the VEGF-C-treated group compared with the control
group (71.9 6 22.7 arbitrary units vs 31.66 45.0 arbitrary
units; P < .01; Fig 3, C).
Protein levels of VEGF-A and VEGF-C in thigh
muscle. There was no statistical difference in VEGF-A
protein expression in the thigh muscle at 7 and 14 days
after limb ischemia in the CD11bþ-treated, VEGF-
C-treated, and control groups (Fig 4, A). However, 7 days
after the intramuscular injection, the CD11bþ cell-treated
group secreted signiﬁcantly more VEGF-C protein in the
thigh muscle after limb ischemia compared with the other
groups (P < .05; Fig 4, B), indicating a crucial role of
VEGF-C in angiogenesis.
Expression of angiogenesis and lymphangiogenesis
marker. After limb ischemia, both the CD11bþ and
VEGF-C groups had signiﬁcantly increased numbers of
von Willebrand factor positive cells and LYVE-1 positive
cells compared with the control group (Fig 5, A). Capillary
density, representing angiogenesis, was signiﬁcantly higher
in the CD11bþ-treated and VEGF-C-treated groups
compared with the control group. Furthermore, in lym-
phangiogenesis, capillary density was signiﬁcantly upregu-
lated in the CD11bþ-treated and VEGF-C-treated groups
compared with the control group (Fig 5, B). These ﬁndings
suggest increased blood ﬂow and functional recovery after
hind limb ischemia when treated with CD11bþ cells or
recombinant VEGF-C. In addition, RT-PCR and histo-
logic analysis showed that VEGFR-1, VEGFR-2, and
VEGFR-3 mRNA and protein were expressed in ischemic
muscle at days 7 and 14 after hind limb ischemia in the
control, CD11bþ, and VEGF-C-treated mice (Fig 5, C).
Effect of VEGFR-2-neutralizing antibody treat-
ment. Recovery of blood ﬂow in ischemic hind limbs of
the CD11bþ and VEGF-C-treated groups was suppressed
by systemic administration of anti-VEGFR-2 (DC101) on
postoperative day 7. Although recovery of blood ﬂow in
ischemic limbs was reduced dramatically, the ischemic
limbs of CD11bþ and VEGF-C-treated groups showed
augmented recovery of hind limb perfusion, and blood
ﬂow returned to the same level of hind limb perfusion
before administration of the anti-VEGFR-2 antibody
(Fig 5, D and E). These results indicate that VEGF-A via
VEGFR-2 signaling may have an important role in angio-
genesis, and that VEGF-C may function as a primary or
adjunctive agent for therapeutic angiogenesis.
DISCUSSION
In this study, we analyzed treatment with CD11bþ
cells derived from BMCs. Furthermore, our data clearly
demonstrate that intramuscular injection of CD11bþ cells
that secreted VEGF-C improved recovery of blood ﬂow
in a murine model of hind limb ischemia. In addition,
CD11bþ treatment could reduce the total number of cell
injections and improve the early operative points of blood
Fig 3. Vascular endothelial growth factor (VEGF)-C promotes neovascularization and functional recovery following
hind limb ischemia. A, Representative laser Doppler perfusion images taken at the indicated intervals for the phosphate-
buffered saline (PBS) control group and the VEGF-C group. Blood perfusion in the ischemic hind limbs was markedly
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Fig 4. Protein levels of vascular endothelial growth factor
(VEGF)-A and VEGF-C in thigh muscle at postoperative days 7
and 14. A, There was no statistically signiﬁcant difference in the
level of VEGF-A expression between all groups (n ¼ 3; mean
[standard deviation]). B, The amount of VEGF-C from the thigh
muscle after limb ischemia, 7 days after the intramuscular injection,
revealed that CD11bþ cell-treated mice had signiﬁcantly increased
levels of VEGF-C compared with the other groups (n ¼ 3; mean
[standard deviation]; *P < .05).
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novelty and advantage of using CD11bþ cells is the secre-
tion of a distinct combination of the angiogenic factor
VEGF-A and the lymphangiogenic factor VEGF-C, and
their substantial in vivo capacity to induce neovasculariza-
tion. In our report, VEGF-A protein was secreted by
cultured CD11bþ cells and a few CD11b cells. In
contrast, VEGF-C was secreted by cultured CD11bþ cells
but not CD11b cells.
Although hind limb ischemia has been improved by
the administration of VEGF-A in animal models, there has
been little improvement in translating the angiogenic
capacity of VEGF-A to beneﬁt PAD patients.24,25 Because
VEGF-A increases vessel permeability, many patients
receiving intramuscular injection of VEGF-A developed
complications such as edema.26 Vascular leakage resulting
in tissue edema is a major problem in therapeutic an-
giogenesis. However, coadministration of VEGF and
angiopoietin-1 has modiﬁed angiogenesis and reduced
vascular permeability in ischemic hind limb models.27,28
These combination gene therapies are currently being
examined in animal models in preparation for translation
to clinical human therapy.
Revascularization has good outcome in patients
with severe PAD, but it is well known that the addition
of chronic venous insufﬁciency to PAD makes treatment
more difﬁcult. Many patients suffer with compromised
occlusive arterial disease and venous congestion. Therefore,
in patients with critical limb ischemia for whom the current
treatment options are not effective, enhancing venous
return and lymphatic drainage from the ischemic limb
may have the potential to improve ischemic limbs. The
VEGF-C is a speciﬁc ligand for the endothelial receptor
tyrosine kinases VEGFR-2 and VEGFR-3, and it mediates
its lymphangiogenic effects through VEGFR-3.29 Further-
more, recent studies showed that blocking VEGFR-3
suppresses angiogenic sprouting and vascular network
formation,30 and that upregulation of Notch-dependent
VEGFR-3 allows angiogenesis without VEGF-A through
VEGFR-2 signaling.31 We focused on VEGF-C and evalu-
ated the ectopic application of recombinant VEGF-C
to induce potent angiogenic effects in vivo. Interestingly,
intramuscular injection of exogenous VEGF-C can
enhance the recovery of blood ﬂow in ischemic limbs
and the function of walking, indicating that enhancingincreased in the VEGF-C group compared with the control g
demonstrated an increase in the ischemic/nonischemic ratio
compared with control group at postoperative days 7 and 14
65.5% 6 11.6% vs 31.1 6 12.0%; P < .05; n ¼ 5-7). Data ar
Tarlov score was signiﬁcantly higher in the VEGF-C group c
and 14 (day 7: 5.256 0.5 vs 1.06 0.81; P < .05; day 14: 5.7
show that the tissue grade was signiﬁcantly higher in the VE
postoperation (4.75 6 0.5 vs 2.85 6 1.06; P < .01; n ¼ 5).
walkway. The period of time during which each of the paw
duration map. The mean paw contact time and paw intensity
each with three replicates, are quantiﬁed in the graph belowlymphatic drainage and venous return accelerates the
recovery of hind limb ischemia. A critical role of VEGF-
C in angiogenesis was suggested by Witzenbichler et al,32
who reported that VEGF-C promotes angiogenesis in
a rabbit model of hind limb ischemia. In accordance
with this ﬁnding, VEGF-C induces neovascularization in
the mouse cornea micropocket assay.33 Concurrently,
Bauer et al34 demonstrated that VEGF-C overexpression,roup. Quantitative analysis of hind limb blood perfusion
, which was signiﬁcantly higher in the VEGF-C group
(day 7: 39.8% 6 12.0% vs 14.8 6 6.7%; P < .01; day 14:
e expressed as mean 6 SEM, n ¼ 5-7 per group. B, The
ompared with the control group at postoperative days 7
56 0.5 vs 3.426 2.37; P < .05; n ¼ 5). Ischemic scores
GF-C group compared with the control group at day 7
C, Video analysis of mice traversing an illuminated glass
s was in contact with the glass is illustrated as a contact
per step for each limb, based on ﬁve separate experiments
the map. *P < .05; **P < .01; ***P < .001.
Fig 5. Effect of CD11bþ cell and vascular endothelial growth factor (VEGF)-C treatment on capillary density 14 days
after the induction of ischemia (n ¼ 5 animals in each group). A, In these representative photomicrographs (original
magniﬁcation 400), von Willebrand factor positive and LYVE-1 positive cells are stained green and red, respectively.
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known to impact ischemic wound healing, such as collagen
constriction in three-dimensional gels, capillary sprouting,
and endothelial progenitor cell invasion and migration
through the extracellular matrix. These studies further
enhance the evidence for VEGF-C as an important angio-
genic factor as well as a lymphangiogenic factor.
To examine the autocrine effects of CD11bþ cells, we
analyzed cultured CD11bþ and CD11b cells by RT-PCR
and Western blotting. Our data show that VEGFR-1 and
VEGFR-3 mRNA and protein, but not VEGFR-2, were
detected in cultured CD11bþ and CD11b cells. These
results indicate that the autocrine effects of CD11bþ cells
are not the main regulator in promoting angiogenesis
through VEGFR-2 for self-renewal. However, not only
VEGFR-1 and VEGFR-3 but also VEGFR-2 was detected
by RT-PCR analysis and immunohistochemical analysis in
ischemic hind limbs. These results indicate that the
VEGF-A and VEGF-C produced by CD11bþ cells or
recombinant VEGF-C activate endothelial cells or
migrated macrophages through VEGFR signaling trans-
duction. In addition, we showed that neutralization of
VEGFR-2 inhibits the recovery of blood ﬂow in ischemic
hind limbs in CD11bþ cell and VEGF-C group mice until
7 days postoperation. In the CD11bþ cell group treated
with VEGFR-2-neutralizing antibody, these results indi-
cate that VEGF-C derived from CD11bþ cell through
VEGFR-3 signaling contributes to the recovery of blood
ﬂow including endogenous VEGF-C secretion. On the
other hand, in the VEGF-C group, recombinant VEGF-
C through VEGFR-3 signaling has a role in angiogenesis
in blood ﬂow recovery in a murine model of hind limb
ischemia including endogenous VEGF-C secretion, as it
was previously reported that VEGF-C (Cys156) induced
a speciﬁc signal through VEGFR-3 but not VEGFR-2.35
These results demonstrate that VEGF-C signaling through
VEGFR-3 has a synergistic action with VEGF-C signal-
ing through VEGFR-2 in angiogenesis. Accordingly,
CD11bþ cells that secrete both VEGF-A and VEGF-C
have a greater potential to accelerate restoration from
ischemia. Furthermore, VEGF-C signaling through
VEGFR-3 plays a critical role in lymphangiogenesis in
improving hind limb ischemia, even if the VEGFR-2B, During angiogenesis, capillary density was signiﬁcantly h
control group (1.88 6 0.34 vs 0.36 6 0.09; P < .001; 0.8
lymphangiogenesis, capillary density was signiﬁcantly upregula
control group (1.89 6 0.26 vs 0.22 6 0.12; P < .001; 1.19 6
***P < .001. C, Reverse transcription-polymerase chain reac
messenger ribonucleic acid (mRNA) expression in thigh mu
phosphate dehydrogenase (G3PDH) was used as the intern
Photomicrographs (original magniﬁcation 400) show re
VEGFR-2, and VEGFR-3. The thigh muscle of each group
micrographs are representative of observations made in three
ﬂow in the ischemic hind limb of the CD11bþ and VEGF-C g
antibody (DC101). The recovery of blood ﬂow in ischem
2-neutralizing antibody was signiﬁcantly suppressed compared
and 7. In the VEGF-C group treated with VEGFR-2-neut
suppressed compared with the VEGF-C group at postoperatinhibitor suppressed the VEGF-A or VEGF-C secreted
from CD11bþ cells.
Although further investigations of the molecular
cascades involved in VEGF-C-mediated effects in ischemia
and in vivo conﬁrmation are needed, these data offer
insights into novel methods to promote angiogenesis and
lymphangiogenesis during ischemia. Collectively, by
focusing on CD11bþ cells and VEGF-C as novel targets,
these ﬁndings might contribute to the development of
new therapeutic strategies for limb ischemia.
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